Just saw that Kyowa Kirin and Amgen are splitting up on rocatinlimab - the Japanese company's taking full control of development now after Amgen did a portfolio review. Interesting move considering the Phase 3 data actually looked solid. Those ROCKET trials from late last year hit all their endpoints for atopic dermatitis treatment, published in The Lancet and everything. Long-term data showed the drug could potentially work with extended dosing too. The mechanism targeting OX40 receptor for moderate-to-severe dermatitis cases is pretty differentiated compared to what's already out there. Amgen's still handling manufacturing, so it's not like they're completely stepping away. Kyowa Kirin seems confident about pushing this forward - they're calling it a key strategic priority. Makes you wonder if this is actually better for the drug's development now that one company owns the whole thing instead of having to coordinate. The dermatitis market's pretty competitive though, so execution will matter. Either way, the clinical data for dermatitis treatment looked promising enough that I'd be watching how this plays out.